NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has closed a Series B financing round raising $27 million.

New York-based Exosome will use the proceeds of the financing to advance development of its proprietary platform technology for preparing nucleic acids from microvesicles, as well commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative disease, and other clinical areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.